PT3654989T - Uso de cladribina para o tratamento de uma doença neuromuscular autoimune - Google Patents

Uso de cladribina para o tratamento de uma doença neuromuscular autoimune

Info

Publication number
PT3654989T
PT3654989T PT187395934T PT18739593T PT3654989T PT 3654989 T PT3654989 T PT 3654989T PT 187395934 T PT187395934 T PT 187395934T PT 18739593 T PT18739593 T PT 18739593T PT 3654989 T PT3654989 T PT 3654989T
Authority
PT
Portugal
Prior art keywords
cladribin
treatment
neuromuscular disease
autoimmune neuromuscular
autoimmune
Prior art date
Application number
PT187395934T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Chord Therapeutics Sa C/O Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa C/O Ares Trading Sa filed Critical Chord Therapeutics Sa C/O Ares Trading Sa
Publication of PT3654989T publication Critical patent/PT3654989T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PT187395934T 2017-07-21 2018-06-28 Uso de cladribina para o tratamento de uma doença neuromuscular autoimune PT3654989T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease

Publications (1)

Publication Number Publication Date
PT3654989T true PT3654989T (pt) 2024-02-28

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187395934T PT3654989T (pt) 2017-07-21 2018-06-28 Uso de cladribina para o tratamento de uma doença neuromuscular autoimune

Country Status (16)

Country Link
US (2) US12171775B2 (enExample)
EP (2) EP3654989B1 (enExample)
JP (1) JP7186214B2 (enExample)
CA (1) CA3095893A1 (enExample)
DK (1) DK3654989T3 (enExample)
ES (1) ES2974423T3 (enExample)
FI (1) FI3654989T3 (enExample)
GB (1) GB2564717A (enExample)
HR (1) HRP20240282T1 (enExample)
HU (1) HUE066238T2 (enExample)
LT (1) LT3654989T (enExample)
PL (1) PL3654989T3 (enExample)
PT (1) PT3654989T (enExample)
RS (1) RS65246B1 (enExample)
SI (1) SI3654989T1 (enExample)
WO (1) WO2019016505A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
AU2024399689A1 (en) 2023-12-14 2026-07-30 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
EP1567945A2 (en) * 2002-11-22 2005-08-31 Transclick, Inc. System and method for speech translation using remote devices
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL2805723T3 (pl) * 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.

Also Published As

Publication number Publication date
HRP20240282T1 (hr) 2024-05-10
EP3654989B1 (en) 2024-01-03
GB201711800D0 (en) 2017-09-06
EP4292663A3 (en) 2024-03-20
US20200163986A1 (en) 2020-05-28
US20250302858A1 (en) 2025-10-02
US12171775B2 (en) 2024-12-24
FI3654989T3 (fi) 2024-03-21
WO2019016505A1 (en) 2019-01-24
GB2564717A (en) 2019-01-23
DK3654989T3 (da) 2024-02-26
EP3654989A1 (en) 2020-05-27
PL3654989T3 (pl) 2024-05-20
LT3654989T (lt) 2024-03-25
SI3654989T1 (sl) 2024-06-28
ES2974423T3 (es) 2024-06-27
HUE066238T2 (hu) 2024-07-28
RS65246B1 (sr) 2024-03-29
JP2020527156A (ja) 2020-09-03
EP4292663A2 (en) 2023-12-20
CA3095893A1 (en) 2019-01-24
JP7186214B2 (ja) 2022-12-08

Similar Documents

Publication Publication Date Title
FR21C1039I2 (fr) Composés destinés à traiter l'amyotrophie spinale
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
PT3631454T (pt) Tratamento de tumores positivos para lag-3
IL256166B (en) Compounds for use in treating neuromuscular disorders
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
PT3562486T (pt) Uso de dexmedetomidina sublingual para o tratamento da agitação
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
PT3681872T (pt) Beta-hidroxietilaminas substituídas com heteroarilo para utilização no tratamento de hiperglicemia
EP3636246A4 (en) COSMETIC PREPARATION WITH WATER-IN-OIL EMULSION
IL272821A (en) TIM-3 antagonists for the treatment and diagnosis of cancer
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
IL256103B (en) Compositions and methods for treating celiac sprue disease
HUE064813T2 (hu) NK-3 receptor antagonisták testzsírfelesleg terápiás vagy kozmetikai kezelésére
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
EP3770951A4 (en) Prober
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
EP3592377A4 (en) DOSAGE FORMS OF TISSUE KALLIKREIN 1
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
EP3840989C0 (en) SLIDING CENTER CONSOLE
EP3806844A4 (en) DOTA COMPOUNDS AND RELATED USES
EP3790928A4 (en) Medical lubricant
HUE053924T2 (hu) Kompozíció cukorbetegség kezelésére
KR101912544B9 (ko) 어큐빈을 포함하는 신경정신 질환의 예방 또는 치료용 조성물
SI3654989T1 (sl) Uporaba kladribina za zdravljenje avtoimunske nevromuskularne bolezni
ES2686909B1 (es) Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas